June 10, 2021—Labcorp and OmniSeq announced the launch of OmniSeq Insight, a next-generation–sequencing, pan-cancer, solid tumor test that combines genomic and immune profiling, including tumor mutational burden, microsatellite instability, and immune gene expression.
Test results are presented in an easy-to-read report that summarizes all FDA-approved therapies and immunotherapies that match the patient’s tumor profile and identifies clinical trials for which a patient may be eligible, within 200 miles of the patient’s home. The report provides evidence-based recommendations specific to the individual test results through the use of a proprietary database sourced from biologic and scientific literature, including National Comprehensive Cancer Network guidelines.
“We are excited to advance our partnership with Labcorp, continuing to provide increased access to oncology care for patients leveraging Labcorp’s extensive footprint and oncology experience,” Margot Schoenborn, CEO of OmniSeq, said in a press statement. “We are making this test available globally to biopharmaceutical customers for incorporation into their clinical trials for biomarker stratification, and to support new precision medicine oncology approaches to drug and companion diagnostic development.”
OmniSeq Insight is available to U.S.-based clinicians through Labcorp and in Canada through Dynacare, a Labcorp company. The test is also available to global biopharmaceutical companies through Labcorp Drug Development.